TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Mar 14, 2023 11:09 JST
Source:
Eisai
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI (lecanemab-Irmb) Two Months After LEQEMBI's FDA Accelerated Approval for Veterans Living with Early Stages of Alzheimer's Disease
Eisai is Proud to Support U.S. Veterans Living With Early Stages of Alzheimer's Disease and Will Continue to Transparently Share our High-Quality Data with the VHA
TOKYO, Mar 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the U.S. Veterans' Health Administration (VHA) is providing coverage of LEQEMBI (lecanemab-irmb) to veterans living with early stages of Alzheimer's disease (AD). VHA healthcare professionals meeting the criteria set forth by the VHA can prescribe LEQEMBI to veterans who fit the VHA's criteria and the U.S. Food and Drug Administration's (FDA) current label. The VHA's careful consideration and timely action to make LEQEMBI available approximately two months after the FDA approved LEQEMBI under the accelerated approval pathway shows its continued commitment to veterans living with AD.
If approved under the traditional pathway, the FDA will update the label for LEQEMBI, which will include new data that has been evaluated by the FDA. Eisai looks forward to sharing additional high-quality data as it becomes available and to continuing discussions with the VHA as the company prepares for the FDA's potential conversion of LEQEMBI's accelerated approval to a traditional approval. Eisai is proud of and humbled by the opportunity to support U.S. veterans as we strive to fulfill our human health care (hhc) mission.
LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibrils*) and insoluble forms of amyloid beta (Aβ), LEQEMBI was approved in the U.S. under the Accelerated approval Pathway for the treatment of AD on January 6, 2023, and was launched in the U.S on January 18, 2023. Treatment with LEQEMBI should only be initiated in patients with mild cognitive impairment or mild dementia stage of disease and confirmed presence of Aβ pathology.
The Accelerated approval was based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of AD, and its continued approval may be contingent upon verification of LEQEMBI's clinical benefit in a confirmatory trial. The FDA has determined that the results of Clarity AD will serve as the confirmatory study to verify the clinical benefit of LEQEMBI.
On the same day that LEQEMBI received its Accelerated approval, Eisai submitted the supplemental Biologics License Application (sBLA) to the FDA for approval under the Traditional pathway. The sBLA was accepted by the FDA on March 3, 2023 and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) date of July 6, 2023. The sBLA is based on the findings from Eisai's recently published large, global confirmatory Phase 3 clinical trial, Clarity AD. LEQEMBI met the primary endpoint and all key secondary endpoints with highly statistically significant results. In November 2022, results of the Clarity AD study were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal, The New England Journal of Medicine.
Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
*Protofibrils are large Aβ aggregated soluble species of 75-500 Kd.1
To learn more, visit www.leqembi.com/, www.eisai.com/news/2023/news202319.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Eisai Inc (U.S.)
Libby Holman
201-753-1945
Libby_Holman@eisai.com
Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44-(0)-786-601-1272
EMEA-comms@eisai.net
Source: Eisai
Sectors: BioTech
Copyright ©2023 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
June 08 2023 12:32 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
June 02 2023 11:20 JST
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
May 26 2023 13:15 JST
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria
May 25 2023 20:02 JST
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023
May 24 2023 17:03 JST
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain
May 20 2023 09:20 JST
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease
May 16 2023 08:27 JST
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
May 08 2023 10:15 JST
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
April 06 2023 17:32 JST
Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
April 04 2023 12:23 JST
More Press release >>
Latest Press Release
Mitsubishi Motors Premieres the All-New Colt for the European Market
Jun 09, 2023 20:28 JST
TOYOTA GAZOO Racing Unveils "GR H2 Racing Concept" at Le Mans 24 Hours
Jun 09, 2023 18:09 JST
Pilot Project for Lifelog-based Health Services in Muraoka-Fukasawa District
Jun 09, 2023 11:47 JST
Crafted Exclusively for the North American Market, Lexus Celebrates the World Premiere of the All-New TX
Jun 09, 2023 10:00 JST
World Premiere of the All-New Lexus GX
Jun 09, 2023 09:30 JST
Hitachi launches "Hitachi Application Reliability Centers Service" in Japan to enable cloud-native operations to drive both agility and reliability
Jun 08, 2023 16:50 JST
Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea
Jun 08, 2023 13:32 JST
MHI Inks MoU with TNB Genco on Clean Energy Technologies to Drive Decarbonization in Malaysia
Jun 07, 2023 15:56 JST
Aiming to Realize an Ever-Better Mobility Society, Toyota Mobility Foundation Selects 12 Teams for 2023 to Work on Activities in the "Mobility for ALL" Category of its Idea Contest
Jun 07, 2023 10:56 JST
JNTO, Mazda Motor Corporation, and TOYOTA GAZOO Racing Jointly Holding "Japan. Endless Discovery." Exhibit on Centenary of Le Mans 24 Hours Race
Jun 06, 2023 17:21 JST
NEC to supply East Micronesia Cable System (EMCS)
Jun 06, 2023 16:18 JST
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
Jun 06, 2023 15:58 JST
Fujitsu 1FINITY Ultra Optical System selected by NTT for next Japan-wide core network
Jun 06, 2023 11:53 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision
Jun 05, 2023 16:00 JST
Lexus Celebrates the World Premiere of the All-New LBX
Jun 05, 2023 15:35 JST
Mitsubishi Shipbuilding to Launch Technical Studies on Ammonia Fuel Supply System for Marine Engines under Development by WinGD
Jun 05, 2023 13:52 JST
Rovanpera increases lead with podium for TOYOTA GAZOO Racing
Jun 05, 2023 11:02 JST
JCB and Joint Stock Commercial Bank for Investment and Development of Vietnam launch the BIDV JCB Ultimate Credit Card in Vietnam
Jun 02, 2023 16:00 JST
Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting
Jun 02, 2023 12:20 JST
More Latest Release >>